# Inetetamab

Source: https://onco.cc/drugs/inetetamab/  
OnCo record `inetetamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.

## Summary

Inetetamab (Cipterbin) is a HER2 antibody developed by 3SBio in Shenyang with an engineered Fc region for stronger antibody-dependent cellular cytotoxicity. The NMPA approved it in June 2020 in combination with vinorelbine for HER2-positive metastatic breast cancer previously treated with chemotherapy, making it the first HER2 antibody developed in China.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Cipterbin
- Tags: china; nmpa-approved
- Modality: Anti-HER2 monoclonal antibody, Fc-engineered
- Mechanism: Binds HER2 on tumour cells, blocking growth signals and recruiting immune cells; its modified Fc region strengthens antibody-dependent cell killing compared with trastuzumab.
- Approvals: CN 2020: HER2-positive metastatic breast cancer after chemotherapy, with vinorelbine

## Sources

- ClinicalTrials.gov: trials of inetetamab: https://clinicaltrials.gov/search?intr=inetetamab

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [3SBio](https://onco.cc/companies/3sbio/)

---
JSON: https://onco.cc/api/v1/entities/inetetamab.json